NCT06766266
CT.gov ↗
Irinotecan liposome II combination therapy regimen
Non-Muscle Invasive Bladder Urothelial Carcinoma
pharma · Non-Muscle Invasive Bladder Urothelial Carcinoma · Nasopharyngeal Cancinoma (NPC)
Chongqing Daxin Pharmaceutical
Chongqing Claruvis Pharmaceutical Co.,
Chongqing Daxin Pharmaceutical trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.
Chongqing, CN HQ
5 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Chongqing, CN
- Employees
- 5
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Chongqing Daxin Pharmaceutical clinical trials
Registry index of 2 ClinicalTrials.gov studies linked to Chongqing Daxin Pharmaceutical programs — each row shows trial ID, program name, phase, status, and indication.
Chongqing Daxin Pharmaceutical trial registry — 2 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Chongqing Daxin Pharmaceutical.